The healthcare scenario in APAC, which houses more than half of the worlds' population, is witnessing a steady increase in the incidence of non-communicable and lifestyle related diseases. Healthcare expenditure in APAC is estimated to grow over 50% in 5 years crossing USD 1.7 trillion — presenting a huge opportunity.
APAC is witnessing enormous challenges related to enabling access to healthcare solutions at affordable pricing and customized to relevant markets. Similar challenges plague the start-up ecosystem - sector knowledge, strategic capital and market applicability.
HealthXCapital is a venture platform converging stakeholders to address:
Access & Affordability — by investing in innovative healthcare startups which help leapfrog existing solutions.
Applicability — by bringing forth a curated network of clinical partners across SE Asia such as Apollo Hospitals who can work deeply with our investments.
Commercialization — by jumpstarting reach in Asia through our strategic partners in insurance, medtech & provider sectors.
HealthXCapital (HXC) is an early stage investment platform providing smart, connected capital to healthcare startups focused on emerging markets in South East Asia and India. HXC is anchored by Jungle Ventures, a leading VC located in Singapore and Apollo Hospitals, the largest healthcare provider in India. We have created a unique model which provides significant competitive advantage to the start-ups we work with.
Disclaimer: HealthXCapital is an early stage venture capital fund. The interest areas listed are a few themes which excite us, however, HealthXCapital is keen to meet disruptive and impactful startups.
Singapore-based healthcare investor HealthXCapital says it expects to close up to three more deals by 2020-end as it looks to capitalise on the flurry of opportunities in the healthtech sector amid the COVID-19 crisis.
Breath Diagnostics Inc. (Breath-Dx), a US-based breath analysis platform, today announced that it has secured an undisclosed amount of investment from HealthXCapital, a Singapore-based healthcare-focused venture capital firm.
With the investment, the two organizations will seek pan-Asian investment, conduct clinical studies, and implement market penetration strategies across the US and Asia, according to a statement. Following the investment, Arda Minocherhomjee, a HealthXCapital representative and a managing partner of the Chicago Growth Fund, will join Breath-Dx’s board of directors.
[..] The startup announced this week that it has raised Series B funding, led by EV Growth, with new investors Alternate Ventures and KDV Capital. Returning investor HealthXCapital also participated. The amount of funding was undisclosed, but sources tell TechCrunch it was $10 million.
[..] CHILD Health Imprints (CHIL), a Singapore-based technology company focusing on neonatal clinical care, on Thursday announced it has raised US$2.3 million in pre-Series A funding. The round was led by Asian early-stage venture capital fund HealthXCapital which focuses on healthcare tech investments in South and South-east Asia. Other participants included Enterprise Singapore’s investment arm Seeds Capital, as well as high net worth individuals.
[..] Asian startups have been raising big investments in the last few years. Investors are also expressing optimism by steadily pumping capital in the sector. The Galen Growth Asia report shows the growth stage companies have got the lion’s share of investment and late stage investors have invested almost over 60 percent of the total capital invested in 2018. Seemant Jauhari, managing partner at Singapore-based venture capital firm HealthXCapital, feels this indicates a great opportunity for early stage health-tech investors lining up a highly curated and de-risked set of deals for late stage investors.
Seemant Jauhari, managing partner at HealthXCapital, discusses the link between infrastructure and modern health care in Asia on CNBC.
[..] HealthXCapital is differentiating itself by occupying a space that no else is now. The Singapore-based healthcare fund is side-stepping the cash burners like genomics and biopharma to focus on devices, diagnostics and digital health. Why? Because disruption in emerging Asia doesn’t need to come in a big bang with fireworks.
Singapore-based HealthXCapital today launched what it claims to be the first healthcare-focused, early-stage fund for emerging markets in Asia.
The US$25 million fund is backed by Indian hospital chain Apollo Hospitals, Eight Roads Ventures – an investment unit of Bermuda-based Fidelity International, Singaporean VC firm Jungle Ventures, and other private investors.
Homage, a caregiving services marketplace, on Tuesday (July 3) said it has raised US$4.15 million (S$5.68 million) in Series A funding.
The round was co-led by Golden Gate Ventures and HealthXCapital (South and South-east Asia’s first healthtech venture capital fund), and participated by existing investors SeedPlus, Juha Pananaan, Lim Dershing and Huang Shao-ning.